Latest News About Ptix Bermuda

I don’t have live access to up-to-the-minute feeds right now, but here’s a concise summary of the most recent publicly available information on PTIX (Protagenic Therapeutics) and PTIX Bermuda-related activities from sources published in late 2024–early 2026:

• PTIX is primarily described in financial and biotech outlets as a small-cap biotech company focused on neuro-active peptide therapies, with PT00114 as its lead candidate. Headlines in 2025–2026 reference Phase 1 results and plans to move into Phase 2 in 2026, including safety, tolerability, and pharmacokinetics updates. [Source coverage around 2025–2026: general biotech finance reporting]
• There have been mentions of delays and Nasdaq-related compliance matters in late 2025, along with quarterly reporting delays reported by various outlets. This suggests ongoing financial and regulatory scrutiny typical for biotech issuers at this stage. [Market/Reuters-style updates from late 2025]
• Bermuda-related activity appears primarily through PTIX Bermuda-facing entities or partnerships, including event/ticketing and contact-oriented references, but public corporate disclosures about Bermuda operations are sparse. The Bermuda-facing PTIX contact page references an office in Hamilton, Bermuda, implying regional engagement or events support capabilities. [PTIX Bermuda contact page]

If you want, I can take a closer look and pull the very latest headlines and filings from specific sources (e.g., major wires, Nasdaq filings, or Bermuda business news) and summarize with direct citations. I can also set up a quick protection-ready briefing with a short timeline of PTIX’s clinical milestones and any Bermuda-related activities.